Navigation Links
Presbyterian Cancer Center to Offer Cancer Patients High-End VMAT Treatments With the Installation of Elekta Infinity
Date:9/15/2008

ATLANTA, Sept. 15 /PRNewswire/ -- Presbyterian Cancer Center - Dallas, a joint venture between Presbyterian Hospital of Dallas and Texas Oncology, PA, recently installed an Elekta Infinity system, enabling the facility to begin treating patients with Volumetric Modulated Arc Therapy (VMAT). Elekta Infinity is the facility's first image guided linear accelerator, and will allow the Center to offer patients shortened treatment times with the highest degree of precision.

"We are excited to be able to provide patients with the benefits afforded by the image guidance and VMAT technology of Elekta Infinity," says Kyle Antes, M.S., Director and Chief Physicist for Presbyterian Cancer Center. "On average, we treat about 65 patients a day, and we anticipate this system will result in increased time savings, highly conformal treatment and a better overall experience for our patients."

VMAT with Elekta Infinity varies the radiation beam during treatment by simultaneously manipulating the gantry position and speed, MLC leaves, dose rate and collimator angle for precise beam shaping without interrupting treatment delivery. As a result, Elekta VMAT delivers more radiation to the target while sparing healthy tissue, in significantly less time. Faster treatment times improve patient comfort, which makes it easier for the patient to remain still during treatment and increases the likelihood of delivering radiation more accurately and safely.

By implementing Elekta VMAT, Antes also anticipates reducing treatment times by half for head and neck patients. What were formerly 30-minute time slots are now only 15 minutes, making it easier for the Center to schedule patients. Patients also experience the benefits of no longer having to lie still, while wearing a tight mask for 30 minutes.

To visualize the prostate, the Presbyterian Cancer Center had previously used gold seeds with MV portal imaging, explains Antes. "Not only did this take longer, we were also faced with the issue of increasing the total dose to the prostate with every MV image. The kilovoltage imaging system integrated on Elekta Infinity imager will alleviate these issues."

The Center intends to hypo-fractionate their prostate treatments with the aid of the image guidance of Elekta VMAT. The system will significantly shorten the number of treatment days for prostate patients, and give the Presbyterian Cancer Center a competitive edge over other centers in the area.

"One thing we're especially grateful for is that Elekta continues to allow all vendor systems to work with their linear accelerator technology," says Antes. "While researching which system to purchase, we found other manufacturers' linacs would have required us to change both our treatment planning system and our record and verify system in order to use their IMRT arc delivery. This wasn't something we were prepared to do."

"We are thrilled to offer our patients VMAT treatment with Elekta Infinity," says Antes. "Incorporating it with our Elekta Precise linear accelerator, MOSAIQ(R) Electronic Medical Record and our Leksell Gamma Knife(R), we're able to provide patients with the best technology for treatment in the region."

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated state of the art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. For more information about Elekta, please visit http://www.elekta.com.


'/>"/>
SOURCE Elekta, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. Novel Technology Breaks Through Cancer Pain
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
11. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... VILLAGE, Calif. , March 24, 2017   ... dermatology and aesthetics company, today announced that Richard ... Officer, effective March 24.   Peterson, who brings ... succeed John Smither , who is retiring at ... Sienna in an advisory capacity. Peterson joins Sienna from ...
(Date:3/23/2017)... 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) (NW ... therapies for solid tumor cancers, today announced that ... it announced last Friday, March 17, 2017. ... investors securities totaling 28,843,692 shares, comprised of 18,843,692 ... shares of Class C Warrants pre-funded at the ...
(Date:3/23/2017)... March 23, 2017 Kineta, Inc., a ... novel therapies in immuno-oncology, today announced the discovery ... molecule compounds that activate interferon response factor 3 ... demonstrate immune-mediated tumor regression in a murine colon ... who demonstrated complete tumor regression to initial drug ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... solutions, today announced the hire of Dr. Sigmund “Sig” Floyd as Vice President ... strategic partnerships and joint development activities. , “Dr. Floyd’s career has spanned 30 ...
Breaking Biology Technology:
(Date:3/22/2017)... , March 21, 2017 Optimove ... used by retailers such as 1-800-Flowers and AdoreMe, ... — Product Recommendations and Replenishment. Using Optimove,s machine learning ... personalized product and replenishment recommendations to their customers ... on predictions of customer intent drawn from a ...
(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in Germany ... ... one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification Systems) ... Used combined in one project, multi-biometric solutions provide a crucial contribution ... ...
(Date:3/7/2017)... Brandwatch , the leading social intelligence company, today ... to uncover insights to support its reporting, help direct future ... UK,s leading youth charity will be using Brandwatch Analytics social listening ... better understanding of the topics and issues that are a priority ... ...
Breaking Biology News(10 mins):